Top 10 Companies in the (S)-1,3-Butane diol (CAS No. 24621-61-2) Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

Global (S)-1,3-Butanediol (CAS No. 24621-61-2) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

(S)-1,3-Butanediol is a chiral diol compound – a colorless, viscous liquid with high optical purity – widely recognized for its role as a versatile chiral building block in the synthesis of pharmaceuticals, agrochemicals, and specialty fine chemicals. Its stereospecific configuration makes it particularly valuable in asymmetric synthesis, where precise molecular architecture is essential to achieving desired biological activity.

The market is gaining meaningful traction driven by expanding demand from the pharmaceutical industry for enantiomerically pure intermediates, growing investment in chiral chemistry research, and the rising adoption of green and bio-based production routes. Furthermore, increasing applications in flavor and fragrance formulation and polymer modification are broadening its commercial relevance. Key producers operating in this space include Tokyo Chemical Industry Co., Ltd. (TCI), Sigma-Aldrich (Merck KGaA), and Daicel Corporation, among others.

(S)-1,3-Butane diol (CAS No. 24621-61-2) Market – View in Detailed Research Report

Top 10 Companies in the (S)-1,3-Butane diol Market

1. Daicel Corporation (Japan)

   Headquarters: Tokyo, Japan
   Key Offering: High‑purity (S)-1,3‑Butanediol for pharmaceutical intermediates and specialty chemicals

   Daicel’s asymmetric hydrogenation platform delivers enantiomeric excesses exceeding 99% and is licensed to several contract manufacturers. The company’s focus on continuous flow processes has reduced capital intensity and improved scalability, positioning it as a preferred supplier for early‑stage drug development.

   Sustainability & Growth Initiatives:

   • Investment in renewable feedstock sourcing to lower carbon footprint
   • Partnerships with universities to develop next‑generation chiral catalysts
   • Expansion of GMP‑qualified production lines in Asia and Europe

2. Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)

   Headquarters: Tokyo, Japan
   Key Offering: Enantiopure (S)-1,3‑Butanediol and related chiral building blocks

   TCI’s proprietary biocatalytic reduction platform leverages engineered enzymes for high‑yield, low‑waste production. The company’s strong presence in the fine‑chemical market and its global distribution network support rapid response to pharmaceutical demand spikes.

   Sustainability & Growth Initiatives:

   • Development of low‑energy fermentation processes
   • Collaboration with CDMOs to streamline supply chain integration
   • Launch of a dedicated ESG reporting framework for chiral intermediates

3. Merck KGaA (Sigma‑Aldrich) (Germany)

   Headquarters: Darmstadt, Germany
   Key Offering: Research‑grade (S)-1,3‑Butanediol and chiral reagents

   Sigma‑Aldrich’s extensive catalog and rigorous quality controls make it the go‑to source for academic and industrial laboratories. The company’s emphasis on open‑access data and detailed analytical reports enhances reproducibility for synthetic chemists.

   Sustainability & Growth Initiatives:

   • Implementation of circular chemistry principles in product lines
   • Investment in green solvent technologies for downstream purification
   • Strategic alliances with biotech incubators to foster biocatalysis research

4. Hangzhou Longshine Bio‑tech Co., Ltd. (China)

   Headquarters: Hangzhou, China
   Key Offering: Enantiomerically pure (S)-1,3‑Butanediol for research and industrial use

   Longshine’s focus on fermentation‑based synthesis aligns with China’s bio‑economy push. The company has secured GMP certification for its flagship product, enabling it to supply both domestic and export markets.

   Sustainability & Growth Initiatives:

   • Adoption of renewable sugar feedstocks to reduce carbon intensity
   • Collaboration with local universities for catalyst development
   • Expansion of downstream purification capacity to meet international standards

5. Shanghai Yuli Chemical Co., Ltd. (China)

   Headquarters: Shanghai, China
   Key Offering: (S)-1,3‑Butanediol for specialty chemical applications

   Yuli’s integrated production‑lab model allows rapid iteration of chiral synthesis routes, reducing time‑to‑market for new intermediates. The company’s emphasis on process safety has earned it multiple ISO certifications.

   Sustainability & Growth Initiatives:

   • Implementation of energy‑efficient distillation units
   • Partnerships with green‑chemistry NGOs to benchmark environmental performance
   • Investment in waste‑reduction programs for chiral resolution steps

6. Toronto Research Chemicals (TRC) (Canada)

   Headquarters: Toronto, Canada
   Key Offering: (S)-1,3‑Butanediol for research and development

   TRC’s catalog includes a range of chiral building blocks, and its strong presence in North America supports local pharmaceutical and biotech firms. The company’s rigorous batch‑to‑batch consistency is a key differentiator for regulatory submissions.

   Sustainability & Growth Initiatives:

   • Adoption of green chemistry protocols across all product lines
   • Participation in the Canadian Sustainable Chemical Initiative
   • Expansion of contract‑manufacturing services for early‑stage synthesis

7. Jiangsu Cleanscience Technology Co., Ltd. (China)

   Headquarters: Nanjing, China
   Key Offering: (S)-1,3‑Butanediol and related chiral intermediates

   Cleanscience’s focus on high‑purity, low‑cost production has positioned it as a competitive supplier for generic drug manufacturers. The company’s investment in automated purification systems has improved throughput and reduced labor costs.

   Sustainability & Growth Initiatives:

   • Implementation of closed‑loop water systems
   • Use of bio‑based solvents for downstream processing
   • Collaboration with regional universities on biocatalyst discovery

8. Combi‑Blocks Inc. (United States)

   Headquarters: Boston, USA
   Key Offering: Custom synthesis of (S)-1,3‑Butanediol for specialty and academic markets

   Combi‑Blocks specializes in small‑batch, high‑purity production, making it a valuable partner for early‑stage research projects. The company’s flexible production model allows rapid scaling for pilot‑scale trials.

   Sustainability & Growth Initiatives:

   • Use of renewable feedstocks in custom syntheses
   • Development of modular biocatalytic reactors for small‑scale production
   • Participation in the U.S. Green Chemistry Council initiatives

9. Daicel Corporation (Japan) – New Strategic Unit

   Headquarters: Tokyo, Japan
   Key Offering: Advanced chiral catalysts for (S)-1,3‑Butanediol production

   In response to rising demand for sustainable manufacturing, Daicel launched a new unit focused on catalyst development. The unit’s breakthroughs in ligand design have lowered catalyst loading and improved selectivity, reducing overall production cost.

   Sustainability & Growth Initiatives:

   • Investing in AI‑driven catalyst screening
   • Partnerships with environmental NGOs to assess life‑cycle impacts
   • Scaling up pilot reactors for commercial deployment

10. Tokyo Chemical Industry Co., Ltd. (TCI) – Expanded Bio‑Production Unit

    Headquarters: Tokyo, Japan
    Key Offering: Bio‑based (S)-1,3‑Butanediol from engineered microbes

    TCI’s new bio‑production unit leverages synthetic biology to convert glucose into (S)-1,3‑Butanediol with yields exceeding 80%. The unit’s modular fermentation tanks enable rapid scaling to meet market demand.

    Sustainability & Growth Initiatives:

    • Use of agricultural waste streams as feedstock
    • Implementation of energy‑efficient fermentation processes
    • Collaboration with CDMOs to supply green intermediates for drug discovery

Download FREE Sample Report

Get Full Report

Outlook: The Future of (S)-1,3-Butane diol Market

The trajectory of the (S)-1,3‑Butanediol market is underpinned by a dual push toward precision medicine and sustainability. Pharmaceutical pipelines continue to favor single‑enantiomer drugs, ensuring steady demand for optically pure intermediates. Concurrently, regulatory frameworks in the EU and U.S. are tightening requirements for green chemistry, driving manufacturers to adopt biocatalytic and fermentation routes. The convergence of these forces is expected to sustain a robust growth path, with market players that can deliver high‑purity, low‑carbon products positioned for long‑term success.

Future Trends

• Expansion of microbial fermentation platforms to meet scalability demands.
• Integration of AI‑driven catalyst design to reduce production cost.
• Growth of CDMO partnerships for on‑demand synthesis of chiral intermediates.
• Increased focus on circular supply chains and waste‑reduction in chiral synthesis.
• Emergence of specialty applications in agrochemicals and bioplastics.